Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation

Fertility and Sterility

Volumn 85, Issue 5, 2006, Pages 1425-1431

  Bairey Merz, C Noel ^a   Johnson, B Delia ^b   Berga, Sarah ^c   Braunstein, Glenn ^a   Reis, Steven E ^b   Bittner, Vera ^d  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Division of Cardiology   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Oral contraceptives, coronary artery disease, postmenopausal, atherosclerosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUESTIONNAIRE; RATING SCALE; RISK FACTOR; SMOKING; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ACADEMIES AND INSTITUTES; AGED; ANGIOGRAPHY; CONTRACEPTIVES, ORAL; CORONARY ARTERIOSCLEROSIS; DRUG UTILIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POSTMENOPAUSE; RISK ASSESSMENT; RISK FACTORS; STATISTICS; UNITED STATES; WOMEN'S HEALTH;

EID: 33646491436     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.01.009     Document Type: Article

References (26)

1. DeStefano F., Merritt R.K., Anda R.F., Casper M.L., and Eaker E.D. Trends in nonfatal coronary heart disease in the United States, 1980 through 1989. Arch Intern Med 153 (1993) 2489-2494
2. Adams M.R., Kaplan J.R., Manuck S.B., Koritnik D.R., Parks J.S., Wolfe M.S., et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. lack of an effect of added progesterone. Atherosclerosis 10 (1990) 1051-1057
3. Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., Speizer F.E., and Hennekens C.H. Menopause and the risk of coronary heart disease in women. N Engl J Med 316 (1987) 1105-1110
4. Barrett-Connor E., and Bush R.L. Estrogen and coronary heart disease in women. JAMA 265 (1991) 1861-1867
5. Wagner J.D., Clarkson T.B., St. Clair R.W., Schwenke D.C., Shively C.A., and Adams M.R. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 88 (1991) 1995-2002
6. Grodstein F., and Stampfer M.J. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 38 (1995) 199-210
7. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al., Heart and Estrogen/progestin Replacement Study (HERS) research group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
8. Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., Shumaker S.A., Snyder T.E., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343 (2000) 522-529
9. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-323
10. Waters D.D., Alderman B.L., Hsia J., Howard B.V., Cobb F.R., Rogers W.J., et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. a randomized controlled trial. JAMA 288 (2002) 2432-2440
11. Rosenberg L., Kaufaman D.W., Helmrich S., Miller D., Stolley P.D., and Shapiro S. Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA 253 (1985) 2965-2969
12. Dunn N., Thorogood M., Faragher B., de Caestecker L., MacDonald T.M., McCollum C., et al. Oral contraceptives and myocardial infarction. results of the MICA case-control study. BMJ 318 (1999) 1579-1583
13. Bairey Merz C.N., Olson M., McGorray S., Pakstis D.L., Zell K., Rickens C.R., et al. Physical activity and functional capacity measurement in women. a report from the NHLBI-sponsored WISE Study. J Womens Health Gender Based Med 9 (2000) 769-777
14. Johnson B.D., Bairey Merz C.N., Braunstein G.D., Berga S.L., Bittner V., Hodgson T.K., et al. Determination of menopausal status in women. the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. J Womens Health 13 (2004) 872-887
15. Bairey Merz C.N., Kelsey S.F., Pepine C.J., Reichek N., Reis S.E., Rogers W.J., et al. The Women's Ischemia Syndrome Evaluation (WISE) Study. protocol design, methodology and feasibility report. J Am Coll Cardiol 33 (1999) 1453-1461
16. Anderson D.C., Hopper B.R., Lasley B.L., and Yen S.S.C. A simple method for the assay of eight steroids in small volumes of plasma. Steroids 28 (1976) 179-185
17. Sharaf B., Pepine C.J., Reis S., Reichek N., Rogers W., Sopko G., et al. Detailed angiographic analysis of women presenting with suspected ischemic chest pain. pilot phase data from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study angiographic core laboratory. Am J Cardiol 87 (2001) 937-941
18. Stampfer M.J., Willett W.C., Goldize G.A., Speizer F.E., and Hennekens C.H. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 319 (1988) 1313-1317
19. Victory R., D'Souza C., Diamond M., McNeeley S.G., Vista-Deck D., and Hendrix S. Adverse cardiovascular disease outcomes are reduced in women with a history of oral contraceptive use. results from the Women's Health Initiative database. Fertil Steril 82 Suppl 2 (2004) S52-S53
20. Engel H.J., Engel E., and Lichtlen P.R. Coronary atherosclerosis and myocardial infarction in young women-role of oral contraceptives. Eur Heart J 4 (1983) 1-6
21. Stampfer M.J., Willett W.C., Colditz G.A., Speizer F.E., and Hennekens C.H. Past use of oral contraceptives and cardiovascular disease. a meta-analysis in the context of the Nurse's Health Study. Am J Obstet Gynecol 163 (1990) 285-291
22. Kaplan J.R., Manuck S.B., Anthony M.S., and Clarkson T.B. Premenopausal social status and hormone exposure predict postmenopausal atherosclerosis in female monkeys. Obstet Gynecol 99 (2002) 381-388
23. Mendelsohn M.E., and Karas R.H. The protective effects of estrogen on the cardiovascular system. New Engl J Med 340 (1999) 1801-1811
24. Prior J.C., Vigna Y.M., Schechter M.T., and Burgess A.E. Spinal bone loss and ovulatory disturbances. New Engl J Med 323 (1990) 1221-1227
25. Solomon C.G., Hu F.B., Danaif A., Rich-Edwards J.E., Stampfer M.J., Willett W.C., et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metabol 87 (2002) 2013-2017
26. Clarkson T.B., Kaplan J.R., Shively C.A., and Klein K.P. Benefits of exogenous oestrogen in inhibiting stress-related coronary artery atherosclerosis. Br J Obstet Gynaecol 103 Suppl 13 (1996) 73-78